Silence Therapeutics Statistics
Total Valuation
SLN has a market cap or net worth of $792.96 million. The enterprise value is $721.02 million.
| Market Cap | 792.96M |
| Enterprise Value | 721.02M |
Important Dates
The last earnings date was Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SLN has 60.21 million shares outstanding. The number of shares has increased by 0.09% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 60.21M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 14.86% |
| Owned by Institutions (%) | 27.68% |
| Float | 44.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,289.36 |
| Forward PS | 1,287.90 |
| PB Ratio | 16.17 |
| P/TBV Ratio | 28.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,172.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.42, with a Debt / Equity ratio of 0.00.
| Current Ratio | 7.42 |
| Quick Ratio | 6.40 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -90.41% and return on invested capital (ROIC) is -60.67%.
| Return on Equity (ROE) | -90.41% |
| Return on Assets (ROA) | -29.65% |
| Return on Invested Capital (ROIC) | -60.67% |
| Return on Capital Employed (ROCE) | -68.76% |
| Weighted Average Cost of Capital (WACC) | 12.01% |
| Revenue Per Employee | $6,989 |
| Profits Per Employee | -$681,284 |
| Employee Count | 88 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, SLN has paid $2,000 in taxes.
| Income Tax | 2,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +138.59% in the last 52 weeks. The beta is 1.41, so SLN's price volatility has been higher than the market average.
| Beta (5Y) | 1.41 |
| 52-Week Price Change | +138.59% |
| 50-Day Moving Average | 10.61 |
| 200-Day Moving Average | 7.28 |
| Relative Strength Index (RSI) | 56.04 |
| Average Volume (20 Days) | 1,941,223 |
Short Selling Information
The latest short interest is 1.84 million, so 5.15% of the outstanding shares have been sold short.
| Short Interest | 1.84M |
| Short Previous Month | 1.57M |
| Short % of Shares Out | 5.15% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.40 |
Income Statement
In the last 12 months, SLN had revenue of $615,000 and -$59.95 million in losses. Loss per share was -$1.27.
| Revenue | 615,000 |
| Gross Profit | 528,000 |
| Operating Income | -64.43M |
| Pretax Income | -59.95M |
| Net Income | -59.95M |
| EBITDA | -63.94M |
| EBIT | -64.43M |
| Loss Per Share | -$1.27 |
Balance Sheet
The company has $72.05 million in cash and $112,000 in debt, with a net cash position of $71.94 million or $1.19 per share.
| Cash & Cash Equivalents | 72.05M |
| Total Debt | 112,000 |
| Net Cash | 71.94M |
| Net Cash Per Share | $1.19 |
| Equity (Book Value) | 38.47M |
| Book Value Per Share | 0.81 |
| Working Capital | 81.57M |
Cash Flow
In the last 12 months, operating cash flow was -$42.26 million and capital expenditures -$3,000, giving a free cash flow of -$42.27 million.
| Operating Cash Flow | -42.26M |
| Capital Expenditures | -3,000 |
| Depreciation & Amortization | 483,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -42.27M |
| FCF Per Share | -$0.70 |
Margins
| Gross Margin | 85.85% |
| Operating Margin | -10,475.61% |
| Pretax Margin | -9,748.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.09% |
| Shareholder Yield | -0.09% |
| Earnings Yield | -7.56% |
| FCF Yield | -5.33% |
Analyst Forecast
The average price target for SLN is $33.00, which is 150.57% higher than the current price. The consensus rating is "Buy".
| Price Target | $33.00 |
| Price Target Difference | 150.57% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -25.81% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SLN has an Altman Z-Score of -6.32 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.32 |
| Piotroski F-Score | 2 |